Search clinical trials for: MORAb-202

Total 3325 results

BrainScope Company, Inc.

Completed

Validation Of TBI Detection System For Head Injured Patients (B-AHEAD III)

Brain Injuries

United States
Neothetics, Inc

Completed

Dose Ranging and Dose Frequency of LIPO-102

Subcutaneous Adipose Tissue Reduction

United States
Xenon Pharmaceuticals Inc.

Completed

A Crossover Study to Evaluate the Safety, Tolerability and Efficacy of XPF-002 in Subjects With Postherpetic Neuralgia (PHN) (XEN402)

Postherpetic Neuralgia

United States
Tranzyme, Inc.

Completed

Safety and Efficacy of Once-daily Oral Administrations of TZP-102 for Gastroparesis in Patients With Diabetes Mellitus

Diabetes Mellitus | Gastroparesis

United States, Denmark, Norway, Sweden, United Kingdom, Poland
Allon Therapeutics

Completed

Study to Evaluate Safety, Tolerability, and Effect of AL208 on Mild Cognitive Impairment Following Coronary Artery Bypass Graft Surgery

Mild Cognitive Impairment

United States, Canada
Puma Biotechnology, Inc.

Completed

A Single Dose Bioequivalence Study Of Neratinib In Healthy Subjects

Healthy

United States
Puma Biotechnology, Inc.

Withdrawn

Study Evaluating The Effect Of A High-Fat Meal On The Pharmacokinetics Of Neratinib

Healthy
BioCryst Pharmaceuticals

Completed

Forodesine in the Treatment of Cutaneous T-Cell Lymphoma

Cutaneous T-cell Lymphoma (CTCL),

United States, Australia, Germany, Italy, Spain, France, Austria, Finland, Switzerland, United Kingdom
Abbott

Completed

A Safety, Tolerability and Pharmacokinetic Study of ABT-102 in Healthy Subjects

Healthy Volunteers

United States
pH Pharma

Completed

Evaluation of PHP-201 Ophthalmic Solution in Patients With Normal Tension Glaucoma

Normal Tension Glaucoma

Korea, Republic of
Heart and Diabetes Center North-Rhine Westfalia
Itamar-Medical, Israel

Completed

Validation of the Peripheral Arterial Tone to Detect Sleep-disordered Breathing in Patients With Chronic Heart Failure

Sleep-Disordered Breathing

Germany
Taiho Oncology, Inc.

Completed

Study Comparing the Bioavailability of TAS-102 Tablets to an Oral Solution Containing Equivalent Amounts of FTD and TPI

Advanced Solid Tumors (Excluding Breast Cancer)

United States
Sun Yat-sen University

Recruiting

Surufatinib Combined With TAS-102 in Third-line and Later-line Therapy of Patients With Advanced Pancreatic Cancer

Pancreatic Neoplasms

China
Fab'entech

Recruiting

Safety and Pharmacokinetics of FBR-002 for the Treatment of Patients Hospitalized With COVID-19 in Need of Supplemental Oxygen and at Risk of Severe Outcome

COVID-19

Greece
Shandong TheraWisdom Biopharma Co., Ltd.

Recruiting

Safety and Tolerability of TWP-201 in Healthy Female Subjects

Infertility

China
National University Hospital, Singapore

Recruiting

A Trial of LONSURF in Recurrent/Metastatic Nasopharyngeal Carcinoma

Recurrent Nasopharyngeal Carcinoma | Metastatic Nasopharyngeal Carcinoma

Singapore
Suzhou Connect Biopharmaceuticals, Ltd.

Completed

A Study to Evaluate the Efficacy and Safety of CBP-201 in Moderate to Severe Atopic Dermatitis in China

Moderate-to-severe Atopic Dermatitis

China
Glyscend, Inc.

Completed

A Study Evaluating the Safety, Tolerability, and Pharmacodynamic Effects of GLY-200 in Type 2 Diabetic Patients

Type 2 Diabetes

United States
Stephen Bagley, MD, MSCE
University of Pennsylvania; Abramson Cancer Center at Penn Medicine

Active, not recruiting

Abemaciclib in Patients With Oligodendroglioma

Oligodendroglioma, Adult

United States
Homology Medicines, Inc

Withdrawn

Safety and Efficacy of HMI-203 in ERT-Treated Adults With MPS II

Mucopolysaccharidosis II

United States, Canada
Kartos Therapeutics, Inc.

Terminated

KRT-232 in Subjects With Relapsed or Refractory Small Cell Lung Cancer

Small Cell Lung Carcinoma | Small-cell Lung Cancer | Small Cell Lung Cancer Extensive Stage | Small Cell Lung Cancer Recurrent

Germany, Spain, France, Australia, United States, Korea, Republic of, Hungary
Suzhou Connect Biopharmaceuticals, Ltd.

Completed

A Study to Assess the Efficacy and Safety of CBP-201 in Adult Subjects With Moderate to Severe Atopic Dermatitis

Moderate-to-severe Atopic Dermatitis

United States, Australia, China, New Zealand
Celgene

Completed

A Study to Evaluate the Efficacy and Safety of CC-220 in Subjects With Active Systemic Lupus Erythematosus

Lupus Erythematosus, Systemic

United States, Belgium, Germany, Spain, Canada, Serbia, Colombia, Poland, Argentina, Brazil, Mexico, Hungary, France, Russian Federation, Italy
Suzhou Connect Biopharmaceuticals, Ltd.

Withdrawn

CBP-201 in Adolescent and Adult Patients With Moderate-to-severe Atopic Dermatitis

Atopic Dermatitis

United States
Jeil Pharmaceutical Co., Ltd.

Completed

The Safety and PK Characteristics of the Co-administration of JLP-2002 and Comparator in Healthy Volunteers

Overactive Bladder(OAB)

Korea, Republic of
Gustave Roussy, Cancer Campus, Grand Paris

Unknown

A Study of Patient Preference Between ODM-201 and Enzalutamide in Men With Metastatic Castrate-resistant Prostate Cancer (ODENZA)

Metastatic Castrate-resistant Prostate (CRPC) Cancer

France
Innocare Pharma Australia Pty Ltd

Completed

A Phase I Study of ICP-022 in Healthy Subjects

Rheumatoid Arthritis | Systemic Lupus Erythematosus

Australia
TWi Biotechnology, Inc.

Completed

A Double-blind, Intra-individual Comparison, POC Trial of AC-203 in EB Patients

Inherited Epidermolysis Bullosa

Taiwan
Celularity Incorporated

Withdrawn

Safety, Hemodynamic Effects and Efficacy of Intramuscular PDA-002 in Subjects Who Have Diabetic Foot Ulcer With Peripheral Arterial Disease

Diabetic Foot | Peripheral Arterial Disease

United States
InQpharm Group

Completed

Efficacy and Safety of IQP-AK-102 in Reducing Appetite

Appetite Regulation | Energy Intake | Appetite Suppression

Germany
Novo Nordisk A/S

Completed

Investigation of the Pharmacokinetics of NNC172-2021, at Two Different Dose Levels, in Healthy Japanese Subjects

Healthy | Congenital Bleeding Disorder | Haemophilia A | Haemophilia B

United Kingdom
Xigen SA

Completed

Efficacy and Safety of XG-102 in Reduction of Post-cataract Surgery Intraocular Inflammation

Pain | Inflammation | Cataract

United States
Centre Hospitalier Universitaire Saint Pierre

Terminated

Detection of Sleep Apnea Syndrome (OSA) in Pregnant Women and Assessment of Impact of OSA on Pregnancy Course

Obstructive Sleep Apnea | Pregnancy | Sleep Apnea Syndrome

Belgium
BrainScope Company, Inc.

Completed

Point-Of-Care TBI Detection System For Head Injured Patients In The Emergency Department (READ-TBI)

Brain Injuries

United States
Taiho Oncology, Inc.

Completed

Study to Evaluate the Cardiac Safety of TAS-102 in Patients With Advanced Solid Tumors

Advanced Solid Tumors (Excluding Breast Cancer)

United States
Neothetics, Inc

Completed

Pilot Study to Determine Safety and Efficacy of Orbital Injections of LIPO-102 in Patients With Symptomatic Exophthalmos Associated With Thyroid-related Eye Disease (TED)

Thyroid-Related Eye Disease

Australia, New Zealand
Genus Oncology, LLC

Completed

Study of GO-203-2C Given Intravenously in Patients With Advanced Solid Tumors Including Lymphomas

Solid Tumors

United States
University of North Carolina, Chapel Hill

Completed

A Study of Inhalation of 20,000 EU CCRE and Mucociliary Clearance (MCC) in Otherwise Healthy Individuals Who Are Current Cigarette Smokers (IRB 09-0259)

Healthy | Cigarette Smoking

United States
Seikagaku Corporation

Completed

Gel-200 Versus Placebo in Osteoarthritis of the Knee

Osteoarthritis of the Knee

United States
4SC AG

Completed

Single Dose Study With 4SC-203 in Healthy Volunteers

Acute Myeloid Leukemia

Germany
Vertex Pharmaceuticals Incorporated

Completed

Drug-Drug Interaction Study of VCH-222 and Telaprevir in Healthy Subjects

Hepatitis C

New Zealand
University of Calgary
Alberta Innovates Health Solutions; Wave View Imaging

Not yet recruiting

Measuring Electrical Properties of Breast Tissues

Healthy | Breast
Nacuity Pharmaceuticals, Inc.

Recruiting

NPI-002 Intravitreal Implant for the Delay of Cataract Progression

Cataract

Australia
Shanghai Bensen Pharmaceutical Co., Ltd.

Not yet recruiting

A Phase I, Open-Label, Dose Escalation and Cohort Expansion Study of BS HH 002.SA in Patients With AML and MDS

Acute Myeloid Leukemia, Myelodysplastic Syndrome
NexImmune Inc.

Suspended

Antigen-specific T Cell Therapy for Patients With Relapsed Refractory Multiple Myeloma

Relapsed Refractory Multiple Myeloma

United States
TenNor Therapeutics (Suzhou) Limited

Completed

A Phase 1, Single-center, Double-blind, Placebo-controlled Study of TNP-2092 Capsules, and the Food Effect Study After Single-dose Oral Administration of TNP-2092 Capsules

Hyperammonemia

China
NewG Lab Pharma

Active, not recruiting

KAT-101 in Subjects With Hepatocellular Carcinoma (HCC)

Hepatocellular Carcinoma | Fibrolamellar Carcinoma

Korea, Republic of
Loxo Oncology, Inc.
Eli Lilly and Company

Available

Expanded Access for the Treatment of Cancers With Rearranged During Transfection (RET) Activation

Breast Cancer | Pancreatic Cancer | Non Small Cell Lung Cancer | Colon Cancer | Medullary Thyroid Cancer | Papillary Thyroid Cancer | Other Solid Tumors With Evidence of Activating RET Alteration

Spain, United States, Australia, France, Germany, Israel, Italy, Japan, New Zealand, Poland, Singapore, Switzerland
Oppilan Pharma Ltd

Active, not recruiting

VTX002 Versus Placebo for the Treatment of Moderately to Severely Active Ulcerative Colitis

Colitis, Ulcerative

United States, Bulgaria, Czechia, France, Georgia, Germany, Hungary, India, Italy, Korea, Republic of, Lithuania, Poland, Serbia, Slovakia
4SC AG

Active, not recruiting

Resminostat for Maintenance Treatment of Patients With Advanced Stage Mycosis Fungoides (MF) or Sézary Syndrome (SS) (RESMAIN)

Lymphoma, T-Cell, Cutaneous | Mycosis Fungoides | Sezary Syndrome

Austria, Spain, Germany, United Kingdom, France, Belgium, Japan, Switzerland, Italy, Poland, Netherlands, Greece

Search clinical trials for: MORAb-202

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Montenegro

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations